[go: up one dir, main page]

WO2003074004A3 - Procede de production d'antigenes - Google Patents

Procede de production d'antigenes Download PDF

Info

Publication number
WO2003074004A3
WO2003074004A3 PCT/US2003/006661 US0306661W WO03074004A3 WO 2003074004 A3 WO2003074004 A3 WO 2003074004A3 US 0306661 W US0306661 W US 0306661W WO 03074004 A3 WO03074004 A3 WO 03074004A3
Authority
WO
WIPO (PCT)
Prior art keywords
producing
antigens
reactive
transglutaminase
cross
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/US2003/006661
Other languages
English (en)
Other versions
WO2003074004A2 (fr
Inventor
Szu-Yi Chou
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Individual
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US10/231,063 external-priority patent/US20030224476A1/en
Priority claimed from US10/231,470 external-priority patent/US7101695B2/en
Priority claimed from US10/231,213 external-priority patent/US20040001848A1/en
Priority claimed from US10/231,298 external-priority patent/US20030219853A1/en
Priority claimed from US10/231,114 external-priority patent/US7485438B2/en
Application filed by Individual filed Critical Individual
Priority to AU2003213718A priority Critical patent/AU2003213718A1/en
Publication of WO2003074004A2 publication Critical patent/WO2003074004A2/fr
Anticipated expiration legal-status Critical
Publication of WO2003074004A3 publication Critical patent/WO2003074004A3/fr
Ceased legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/10—Transferases (2.)
    • C12N9/1025—Acyltransferases (2.3)
    • C12N9/104—Aminoacyltransferases (2.3.2)
    • C12N9/1044—Protein-glutamine gamma-glutamyltransferase (2.3.2.13), i.e. transglutaminase or factor XIII
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0007—Nervous system antigens; Prions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4711—Alzheimer's disease; Amyloid plaque core protein
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/64—Medicinal preparations containing antigens or antibodies characterised by the architecture of the carrier-antigen complex, e.g. repetition of carrier-antigen units
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Microbiology (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Veterinary Medicine (AREA)
  • Zoology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Immunology (AREA)
  • Public Health (AREA)
  • Mycology (AREA)
  • Molecular Biology (AREA)
  • Biomedical Technology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Oncology (AREA)
  • Neurology (AREA)
  • Wood Science & Technology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Toxicology (AREA)
  • Neurosurgery (AREA)
  • General Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Enzymes And Modification Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)

Abstract

Des modes de réalisation de l'invention concernent en général des procédés et des compositions permettant de produire des antigènes polyvalents, des antigènes spécifiques de maladies, des composés réactifs à la transglutaminase, et des transglutaminases recombinées. L'invention concerne également un procédé de production d'un composé réticulé par un agent biologique. L'invention concerne également un procédé de production d'un antigène réticulé et un procédé d'utilisation de produits réticulés utilisés en tant qu'antigènes afin d'immuniser des animaux et d'induire de fortes réponses immunitaires. L'invention concerne également un procédé de production d'un antigène spécifique de la maladie d'Alzheimer. L'invention concerne également un procédé de production d'un antigène polyvalent pour au moins deux maladies. Ces compositions et ces antigènes sont ainsi préparés et administrés afin d'immuniser des animaux et d'induire de fortes réponses immunitaires. L'invention concerne en outre des transglutaminases recombinées purifiées réactives à une variété étendue de composés et qui présentent une grande activité de substrat. L'invention concerne enfin un procédé permettant de lier un ou plusieurs résidus d'amino-acides à un composé à faire réagir avec de la transglutaminase, y compris pour des composés non réactifs à la transglutaminase.
PCT/US2003/006661 2002-03-01 2003-03-03 Procede de production d'antigenes Ceased WO2003074004A2 (fr)

Priority Applications (1)

Application Number Priority Date Filing Date Title
AU2003213718A AU2003213718A1 (en) 2002-03-01 2003-03-03 Method of producing antigens

Applications Claiming Priority (14)

Application Number Priority Date Filing Date Title
US36116602P 2002-03-01 2002-03-01
US60/361,166 2002-03-01
US36344502P 2002-03-08 2002-03-08
US60/363,445 2002-03-08
US10/231,470 2002-08-28
US10/231,063 US20030224476A1 (en) 2002-03-01 2002-08-28 Method of producing transglutaminase reactive compound
US10/231,298 2002-08-28
US10/231,213 2002-08-28
US10/231,470 US7101695B2 (en) 2002-03-01 2002-08-28 Method of producing transglutaminase having broad substrate activity
US10/231,213 US20040001848A1 (en) 2002-03-01 2002-08-28 Method of producing disease-specific antigens
US10/231,298 US20030219853A1 (en) 2002-03-01 2002-08-28 Method of cross-linking a compound
US10/231,114 US7485438B2 (en) 2002-03-01 2002-08-28 Method of producing polyvalent antigens
US10/231,063 2002-08-28
US10/231,114 2002-08-28

Publications (2)

Publication Number Publication Date
WO2003074004A2 WO2003074004A2 (fr) 2003-09-12
WO2003074004A3 true WO2003074004A3 (fr) 2006-08-10

Family

ID=27792403

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2003/006661 Ceased WO2003074004A2 (fr) 2002-03-01 2003-03-03 Procede de production d'antigenes

Country Status (2)

Country Link
AU (1) AU2003213718A1 (fr)
WO (1) WO2003074004A2 (fr)

Cited By (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8691224B2 (en) 2005-11-30 2014-04-08 Abbvie Inc. Anti-Aβ globulomer 5F7 antibodies
US8877190B2 (en) 2006-11-30 2014-11-04 Abbvie Inc. Aβ conformer selective anti-Aβ globulomer monoclonal antibodies
US8895004B2 (en) 2007-02-27 2014-11-25 AbbVie Deutschland GmbH & Co. KG Method for the treatment of amyloidoses
US8961544B2 (en) 2010-08-05 2015-02-24 Lifebond Ltd. Dry composition wound dressings and adhesives comprising gelatin and transglutaminase in a cross-linked matrix
US8987419B2 (en) 2010-04-15 2015-03-24 AbbVie Deutschland GmbH & Co. KG Amyloid-beta binding proteins
US9017664B2 (en) 2006-12-15 2015-04-28 Lifebond Ltd. Gelatin-transglutaminase hemostatic dressings and sealants
US9176150B2 (en) 2003-01-31 2015-11-03 AbbVie Deutschland GmbH & Co. KG Amyloid beta(1-42) oligomers, derivatives thereof and antibodies thereto, methods of preparation thereof and use thereof

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1711208A2 (fr) * 2004-01-28 2006-10-18 Curix APS Methodes de prevention et de traitement de la maladie d'alzheimer et d'autres maladies associees aux amyloides
TW200726482A (en) * 2005-06-30 2007-07-16 Merck & Co Inc Method for preparing a covalently cross linked oligomer of amyloid beta peptides
PL1976877T5 (pl) 2005-11-30 2017-09-29 Abbvie Inc Przeciwciała monoklonalne przeciwko białku amyloidu beta oraz ich zastosowania
EP2054436A1 (fr) * 2006-08-18 2009-05-06 Novo Nordisk Health Care AG Variants de transglutaminase dotés d'une spécificité améliorée
US20100087371A1 (en) * 2007-02-22 2010-04-08 Sean Hu Transglutaminase Variants with Improved Specificity
WO2009153751A2 (fr) * 2008-06-18 2009-12-23 Lifebond Ltd Procédé de réticulation enzymatique d'une protéine
CN102124058B (zh) 2008-06-18 2014-05-28 生命连结有限公司 改进的交联组合物
AU2010334412B2 (en) 2009-12-22 2016-02-04 Lifebond Ltd Modification of enzymatic crosslinkers for controlling properties of crosslinked matrices
EP2603524A1 (fr) 2010-08-14 2013-06-19 AbbVie Inc. Protéines de liaison bêta-amyloïdes
US11998654B2 (en) 2018-07-12 2024-06-04 Bard Shannon Limited Securing implants and medical devices

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4544638A (en) * 1984-05-18 1985-10-01 The Regents Of The University Of California Synthesis of cross-links in the helical domain of collagen using pyridoxal 5-phosphate and copper or iron
US6010871A (en) * 1994-09-29 2000-01-04 Ajinomoto Co., Inc. Modification of peptide and protein

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4544638A (en) * 1984-05-18 1985-10-01 The Regents Of The University Of California Synthesis of cross-links in the helical domain of collagen using pyridoxal 5-phosphate and copper or iron
US6010871A (en) * 1994-09-29 2000-01-04 Ajinomoto Co., Inc. Modification of peptide and protein

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
DE JONG G.A.H. ET AL: "Purification and substrate specificity of transglutaminase from blood and Streptoverticillium mobaraense", JOUR. AGRIC FOOD CHEM., vol. 49, 2001, pages 3389 - 3393, XP003001875 *
KAHLEM P. ET AL.: "Peptides containing glutamine repeats as substrates for transglutaminase catalyzed cross-linking: Relevance to diseases of the nervous system", PROC. NATL. ACAD. SCI. USA, vol. 93, 1996, pages 14580 - 14585, XP000918974 *

Cited By (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9176150B2 (en) 2003-01-31 2015-11-03 AbbVie Deutschland GmbH & Co. KG Amyloid beta(1-42) oligomers, derivatives thereof and antibodies thereto, methods of preparation thereof and use thereof
US8691224B2 (en) 2005-11-30 2014-04-08 Abbvie Inc. Anti-Aβ globulomer 5F7 antibodies
US9540432B2 (en) 2005-11-30 2017-01-10 AbbVie Deutschland GmbH & Co. KG Anti-Aβ globulomer 7C6 antibodies
US8877190B2 (en) 2006-11-30 2014-11-04 Abbvie Inc. Aβ conformer selective anti-Aβ globulomer monoclonal antibodies
US9359430B2 (en) 2006-11-30 2016-06-07 Abbvie Inc. Abeta conformer selective anti-Abeta globulomer monoclonal antibodies
US9394360B2 (en) 2006-11-30 2016-07-19 Abbvie Inc. Aβ conformer selective anti-Aβ globulomer monoclonal antibodies
US9017664B2 (en) 2006-12-15 2015-04-28 Lifebond Ltd. Gelatin-transglutaminase hemostatic dressings and sealants
US8895004B2 (en) 2007-02-27 2014-11-25 AbbVie Deutschland GmbH & Co. KG Method for the treatment of amyloidoses
US8987419B2 (en) 2010-04-15 2015-03-24 AbbVie Deutschland GmbH & Co. KG Amyloid-beta binding proteins
US8961544B2 (en) 2010-08-05 2015-02-24 Lifebond Ltd. Dry composition wound dressings and adhesives comprising gelatin and transglutaminase in a cross-linked matrix

Also Published As

Publication number Publication date
WO2003074004A2 (fr) 2003-09-12
AU2003213718A1 (en) 2003-09-16
AU2003213718A8 (en) 2003-09-16

Similar Documents

Publication Publication Date Title
WO2003074004A3 (fr) Procede de production d'antigenes
WO2006031560A3 (fr) Procede pour concentrer des anticorps, et produits therapeutiques correspondants
WO2007002261A3 (fr) Anticorps bloquant il-1$g(b) et leurs fragments
WO2004039956A3 (fr) Compositions et methodes de traitement de maladies liees au systeme immunitaire
EP1373301A4 (fr) Diminution de l'antigenicite de proteines de fusion
CA2290485A1 (fr) Procede de production de proteines non immunogenes
WO2002020569A3 (fr) Genes mammaliens, reactifs et methodes associes
WO2003017935A3 (fr) Anticorps humains specifiques diriges contre l'interleukine 15 (il-15)
WO2004043407A3 (fr) Methodes et produits de traitement des infections staphylococciques
WO2000053758A3 (fr) Compositions et methodes de traitement des maladies immunitaires
MXPA05007211A (es) Composicion farmaceutica que comprende una region de fc de inmunoglobulina como un vehiculo.
EP2292664A3 (fr) Molécules des-immunisées liant le CD3 multispecifiques
WO2004076620A3 (fr) Anticorps humains specifiques de l'interleukine 15 (il-15)
DE602005001445D1 (de) N-terminal monopegylierte menschliche wachstumshormon-konjugate, verfahren zu ihrer herstellung und ihre anwendung
WO2010044889A3 (fr) Isolats de torque teno virus (ttv) et compositions associées
WO2012075173A3 (fr) Compositions et procédé de désimmunisation de protéines
ATE321859T1 (de) B2microglobulin fusionsproteine und varianten mit hoher affinität
WO2000073452A3 (fr) Compositions et methodes de traitement de maladies liees a l'immunite
WO2002012899A3 (fr) Peptides presents par cellules
WO1999046379A3 (fr) Proteines receptrices humaines; reactifs et procedes associes
WO2001057219A3 (fr) Cytokines mammaliennes, leurs recepteurs, reactifs et procedes correspondants
WO2001040465A3 (fr) Compositions et procedes de traitement de maladies d'ordre immunologique
WO2002074921A3 (fr) Methodes d'isolement de proteines exprimees au moyen de cellules dendritiques
WO2002044737A3 (fr) Compositions pour applications diagnostiques et therapeutiques et methodes associees au recepteur couple aux proteines g (gpcr) le recepteur anaphylatoxine c3a
WO2005121178A3 (fr) Chromatographie d'immunoaffinite au moyen de marques epitopes pour des anticorps monoclonaux sensibles au polyol

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ OM PH PL PT RO RU SC SD SE SG SK SL TJ TM TN TR TT TZ UA UG UZ VC VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IT LU MC NL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
122 Ep: pct application non-entry in european phase
NENP Non-entry into the national phase

Ref country code: JP

WWW Wipo information: withdrawn in national office

Country of ref document: JP